2D-2D for Healthy Subjects (HS)

Phase-Based Progress Estimates
Oklahoma State University, Stillwater, OK
Healthy Subjects (HS)
Modality - 3D-2D - Behavioral
< 18
All Sexes
What conditions do you have?

Study Summary

The goal of this work is to address increasing concerns about young children's digital media exposure and language outcomes by testing how the times course of word learning unfolds in digital environments and the cascading impact of digital media on vocabulary outcomes. The findings will have important implications for understanding when and where optimal word learning from media can occur.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 1 minute

1 minute
Generalization performance

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

4 Treatment Groups

1 of 4
1 of 4
1 of 4
1 of 4
Active Control
Experimental Treatment

200 Total Participants · 4 Treatment Groups

Primary Treatment: 2D-2D · No Placebo Group · N/A

Experimental Group · 1 Intervention: Modality - 2D-2D · Intervention Types: Behavioral
Experimental Group · 1 Intervention: Modality - 2D-3D · Intervention Types: Behavioral
Experimental Group · 1 Intervention: Modality - 3D-2D · Intervention Types: Behavioral
3D-3DNoIntervention Group · 1 Intervention: 3D-3D · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 minute

Trial Background

Prof. Sarah Kucker, Assistant Professor
Principal Investigator
Oklahoma State University
Closest Location: Oklahoma State University · Stillwater, OK
2017First Recorded Clinical Trial
3 TrialsResearching Healthy Subjects (HS)
13 CompletedClinical Trials

Eligibility Criteria

Age < 18 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.